GlassScriptPhysician profile
Cody J Connor
NPI 1447631619
$28,060.39
in general payments reported to CMS, 2019-2025
30 companies · $3,450 in 2025
The $3,450 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $655 · 2021: $749 · 2022: $11K · 2023: $7,473 · 2024: $3,219 · 2025: $3,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,243 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,780 · Education: $99.99 · Travel and Lodging: $19.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,242.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,780.00 |
| Education | $99.99 |
| Travel and Lodging | $19.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $15,641.30 | 2021-2025 | Opzelura |
| Abbvie INC. | $1,753.03 | 2021-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,375.61 | 2019-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $1,127.13 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $978.32 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $886.80 | 2019-2024 | Ilumya, Winlevi |
| Amgen INC. | $825.01 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $819.28 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $700.22 | 2020-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $695.41 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Leo Pharma INC. | $490.61 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $451.56 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $410.10 | 2021-2025 | |
| Galderma Laboratories, L.P. | $385.09 | 2020-2025 | Nemluvio, Aklief, Oracea |
| Arcutis Biotherapeutics, INC. | $348.57 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $228.14 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $194.82 | 2023-2025 | Sotyktu |
| Dermira, INC. | $125.00 | 2019 | |
| Vyne Pharmaceuticals INC. | $111.70 | 2021 | |
| Organon LLC | $102.39 | 2025 | Vtama |
| Allergan, INC. | $97.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.02 | 2023-2024 | Spevigo |
| Epi Health, LLC | $54.54 | 2020-2021 | |
| Almirall LLC | $53.46 | 2023-2024 | Klisyri, Seysara |
| Mayne Pharma Commercial LLC | $37.19 | 2021-2023 | |
| Journey Medical Corporation | $23.88 | 2022 | |
| Celgene Corporation | $16.97 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.00 | 2024 | Nuzyra |
| Prugen, INC. Pharmaceuticals | $14.05 | 2020 | |
| Sebela Pharmaceuticals INC. | $13.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.